CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 131 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2017. The put-call ratio across all filers is 1.26 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2018 | $442,000 | -4.5% | 2,239,826 | +118.1% | 0.00% | – |
Q3 2018 | $463,000 | -11.0% | 1,027,121 | -0.6% | 0.00% | – |
Q2 2018 | $520,000 | -80.2% | 1,033,790 | -8.1% | 0.00% | -100.0% |
Q1 2018 | $2,620,000 | -16.6% | 1,124,654 | +1.7% | 0.00% | 0.0% |
Q4 2017 | $3,140,000 | +14.7% | 1,105,741 | +15.5% | 0.00% | 0.0% |
Q3 2017 | $2,738,000 | +17.7% | 957,664 | +1.7% | 0.00% | 0.0% |
Q2 2017 | $2,326,000 | -27.1% | 941,824 | +6.6% | 0.00% | 0.0% |
Q1 2017 | $3,190,000 | +14.7% | 883,786 | +12.5% | 0.00% | 0.0% |
Q4 2016 | $2,781,000 | -9.7% | 785,672 | +3.0% | 0.00% | -50.0% |
Q3 2016 | $3,080,000 | +4.1% | 762,569 | +13.1% | 0.00% | 0.0% |
Q2 2016 | $2,959,000 | +16.9% | 674,181 | +0.7% | 0.00% | +100.0% |
Q1 2016 | $2,531,000 | -75.5% | 669,587 | +1.7% | 0.00% | -83.3% |
Q4 2015 | $10,326,000 | +54.0% | 658,605 | +3.5% | 0.01% | +50.0% |
Q3 2015 | $6,705,000 | -58.4% | 636,205 | -0.6% | 0.00% | -55.6% |
Q2 2015 | $16,135,000 | -4.7% | 639,806 | +5.3% | 0.01% | -10.0% |
Q1 2015 | $16,936,000 | +77.7% | 607,692 | +16.3% | 0.01% | +66.7% |
Q4 2014 | $9,532,000 | +44.6% | 522,350 | +2.7% | 0.01% | +50.0% |
Q3 2014 | $6,593,000 | -20.5% | 508,763 | +0.1% | 0.00% | -20.0% |
Q2 2014 | $8,293,000 | -7.2% | 508,173 | +0.5% | 0.01% | -16.7% |
Q1 2014 | $8,937,000 | -19.3% | 505,798 | +10.6% | 0.01% | -25.0% |
Q4 2013 | $11,071,000 | -25.0% | 457,314 | +9.7% | 0.01% | -33.3% |
Q3 2013 | $14,765,000 | +180.3% | 416,742 | +23.5% | 0.01% | +140.0% |
Q2 2013 | $5,268,000 | – | 337,465 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Byrne Asset Management LLC | 86 | $2,000 | 0.00% |